FDA Corrects Notice on Patent Extension for NeutrexinTM

Summary

The FDA is correcting a notice from August 30, 1994, regarding the regulatory review period for patent extension of NeutrexinTM, due to an error in one of the dates and the need for additional clarification between the patent applicant's records and FDA's records.